Galil Medical Announces Introduction of IceRod® PLUS Cryoablation Needle

Share Article

Expanded product portfolio offers physicians more choices in treating patients

Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today they received FDA 510k clearance to market their new IceRod® PLUS Cryoablation Needle.

The IceRod PLUS Cryoablation Needle is the latest in Galil Medical’s line of 17 gauge (1.47mm) ultra thin needles.

This new needle eliminates frost buildup along the needle shaft during percutaneous and laparoscopic cryoablation procedures. Additionally, this new needle creates a very predictable ice ball size, shape, and zone of ablation.

The IceRod PLUS needle further enhances the IceRod family of needles, which is already the smallest, lightest and lowest profile cryoablation needle on the market.

“IceRod PLUS needle is the first of several new products Galil Medical will introduce in the coming months and years, and is a direct result of our continued commitment to significantly invest in new product innovations”, commented Martin J. Emerson, President and CEO of Galil Medical.

The company is also planning to launch a new cryoablation system within the next 12 months, as well as another new cryoablation needle that will produce a larger zone of ablation. This new needle will potentially reduce procedure times, provide clinician’s more choice to improve patient outcomes, and provide flexibility to treat a greater range of patients.

“Galil Medical is the only company solely committed to advancing cryotherapy over a broad range of applications,” Emerson continued; “We believe that the introduction of IceRod Plus needles will further solidify our position as the preeminent cryotherapy company in the world. Our goal is to provide our clinicians with a broad range of product choices, allowing them the flexibility to treat a wider range of patients.”

About Galil Medical Galil Medical is a global leader in delivering innovative cryotherapy solutions. The company is addressing patient conditions across multiple physician specialties; treatment areas include conditions affecting bone, kidney, liver, lung and prostate, as well as targeted pain and nerve applications. Company offices are located in Arden Hills, Minnesota; Yokneam, Israel; and London, United Kingdom. Shareholders include Thomas, McNerney & Partners, The Vertical Group, and Investor Growth Capital.

Contact information:

Martin J. Emerson
President and CEO, Galil Medical
Tel: +1 651 287 5050
Email: marty(dot)emerson(at)galilmedical(dot)com

Tres Glenn
Vice-President, Global Marketing, Galil Medical
Tel: +1 919 673 5863
Email: tres(dot)glenn(at)galilmedical(dot)com


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tres Glenn
Galil Medical
(919) 673-5863
Email >